Combination Therapies 2

Section I - Mechanism of Action and Rationale for the Use of Biological Response Modifiers, Differentiating Agents and Nucleoside Analogues in Combination.- 1. Cytokine Synergy in Immunotherapy.- 2. Monitoring Combination Therapy Trials: New Challenges for the Clinical Laboratory.- 3. IL-2-Based Consolidative Immunotherapy After Autologous Bone Marrow Transplantation.- 4. Tumor Immunogenicity Induced by the Local. Occurrence of IL-2.- 5. Thymosin ?1: Chemistry, Mechanism of Action and Clinical Applications.- 6. Combination Therapy with Thymosin ?1 and Cytokines in the Treatment of Cancer and Infectious Diseases.- 7. Effect of Thymosin a1 on Cocaine-induced Inhibition of T-Cell Dependent Murine Immune Response.- 8. Regulation of Gene Expression by Interferons.- 9. Interactions Between Tumor Necrosis Factor Alpha and Glucocorticoid Hormones in the Regulation of Tumor Cell Growth In Vitro.- 10. Behavioural, Pyrogenic and Electrocortical Effects of Tumor Necrosis Factor-Alpha Given Intracerebrally in Rats.- 11. Biological Significance and Therapeutic Potential of Tumor-Associated Leukocytes.- 12. Septic Shock Pathophysiology: Focus on Therapeutic Approach.- 13. Differentiating Agents and Cancer Therapy. Role of Cellular Lipid Peroxidation and its Product 4-Hydroxynonenal in the Control of Cell Proliferation and Differentiation.- 14. Inhibition of HIV Replication and Enhancement of Immune Functions by the Acyclic Nucleoside Phosphonate 9-(2-Phosphonyl-Methoxyethyl) Adenine (PMEA).- 15. Modulation of Inflammatory Cytokines by a Receptor Antagonist, Autoantibodies, and Fever.- Section II - Combination Chemotherapy and Brm Therapy in the Treatment of Cancer.- 16. Cancer Immunochemotherapy: Preliminary Studies with Triazene Compounds.- 17. Thymosin ?1 and ?-Interferon withCisplatin and Etoposide in Advanced Non-Small Cell Lung Cancer: A Phase II Study.- 18. Combination of Chronic Indomethacin and Intermittent IL-2 Therapy in the Treatment of Disseminated Cancer.- 19.